{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:49Z","timestamp":1740144049026,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["200812 (NCT02729051)","CTT116853 (NCT02345161)","CTT116855 (NCT02164513)"],"award-info":[{"award-number":["200812 (NCT02729051)","CTT116853 (NCT02345161)","CTT116855 (NCT02164513)"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40262-019-00794-w","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T02:02:47Z","timestamp":1563501767000},"page":"67-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetic Analysis of Fluticasone Furoate\/Umeclidinium Bromide\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"59","author":[{"given":"Rashmi","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colm","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobh\u00e1n","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Birk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malek","family":"Okour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-4593","authenticated-orcid":false,"given":"David A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"794_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2018. Available from: \nhttps:\/\/goldcopd.org\/wp-content\/uploads\/2017\/11\/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf\n\n. Accessed 15 Mar 2019."},{"key":"794_CR2","doi-asserted-by":"publisher","first-page":"e105296","DOI":"10.1371\/journal.pone.0105296","volume":"9","author":"KE Wurst","year":"2014","unstructured":"Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9:e105296.","journal-title":"PLoS One."},{"key":"794_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/COPD.S122013","volume":"12","author":"JC Simeone","year":"2017","unstructured":"Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, et al. Initiation of triple therapy maintenance treatment among patients with COPD in US. Int J Obstruct Pulmon Dis. 2017;12:73\u201383.","journal-title":"Int J Obstruct Pulmon Dis."},{"key":"794_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438\u201346.","journal-title":"Am J Respir Crit Care Med."},{"key":"794_CR5","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner G, Day N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med."},{"key":"794_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12931-018-0724-0","volume":"19","author":"PR Bremner","year":"2018","unstructured":"Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA. Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19:19.","journal-title":"Respir Res."},{"key":"794_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40262-013-0078-1","volume":"52","author":"A Allen","year":"2013","unstructured":"Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet. 2013;52:885\u201396.","journal-title":"Clin Pharmacokinet."},{"key":"794_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-014-0143-4","volume":"53","author":"N Goyal","year":"2014","unstructured":"Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2014;53:637\u201348.","journal-title":"Clin Pharmacokinet."},{"key":"794_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s13318-015-0303-4","volume":"41","author":"S Siederer","year":"2016","unstructured":"Siederer S, Allen A, Yang S. Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in subjects with chronic obstructive pulmonary disease. Eur J Drug Metab Pharmacokinet. 2016;41:743\u201358.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"794_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401\u201321.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"794_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185\u2013202.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"794_CR12","unstructured":"US Food and Drug Administration. Breo\u00ae Ellipta\u00ae highlights of prescribing information. Updated May 2017. Available from: \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204275s012lbl.pdf\n\n. Accessed May 2019."},{"key":"794_CR13","unstructured":"US Food and Drug Administration. Trelegy\u00ae Ellipta\u00ae highlights of prescribing information. Updated September 2017. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209482s000lbl.pdf\n\n. Accessed May 2019."},{"key":"794_CR14","doi-asserted-by":"crossref","unstructured":"Halpin DMG, Bardsley S, Criner G, Dransfield M, Han MK, Jones CE, et al. The IMPACT trial: single inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: analysis according to smoking status. Abstract presented at the ATS International Conference; 17\u201322 May, 2019; Dallas (TX). Available from: \nhttps:\/\/www.abstractsonline.com\/pp8\/#!\/5789\/presentation\/19667\n\n. Accessed May 2019.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A3339"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00794-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:30:35Z","timestamp":1595028635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00794-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"19 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Funding for these studies [200812 (NCT02729051); CTT116853 (NCT02345161); CTT116855 (NCT02164513)] was provided by GlaxoSmithKline. The funders of the study had a role in the study design, data analysis, data interpretation, and writing of the report. The corresponding author had full access to all the data and the final responsibility to submit for publication. All authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rashmi Mehta, Ruby Birk, Malek Okour, and David A. Lipson are employees of GSK and hold stock in the company. Colm Farrell and Siobh\u00e1n Hayes are employees of ICON; ICON received funding from GSK to conduct the analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocols were approved by the appropriate institutional review boards and conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki. The human biological samples were sourced ethically and their research use was in accordance with the terms of the informed consents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects enrolled in the studies included in this analysis were required to provide written informed consent prior to any study-related procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Anonymized individual participant data and study documents can be requested for further research from .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}